PDF herunterladen
Thromb Haemost 2021; 121(05): 650-658
DOI: 10.1055/s-0040-1721144
Atherosclerosis and Ischaemic Disease

Circulating Amyloid Beta 1–40 Is Associated with Increased Rate of Progression of Atherosclerosis in Menopause: A Prospective Cohort Study

Irene Lambrinoudaki‡   *
1   Menopause Clinic, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Dimitrios Delialis‡   *
2   Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
,
Georgios Georgiopoulos‡   *
2   Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
3   School of Biomedical Engineering & Imaging Sciences, Rayne Institute, St. Thomas' Hospital, London, United Kingdom
,
Simon Tual-Chalot
4   Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
,
Nikolaos I. Vlachogiannis
4   Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
,
Raphael Patras
2   Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
,
Evmorfia Aivalioti
2   Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
,
Eleni Armeni
1   Menopause Clinic, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Areti Augoulea
1   Menopause Clinic, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Nikolaos Tsoltos
1   Menopause Clinic, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Anastasia Soureti
1   Menopause Clinic, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Konstantinos Stellos   **
4   Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
5   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
,
Kimon Stamatelopoulos   **
1   Menopause Clinic, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
4   Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
› Institutsangaben Funding K. Stellos is supported by grants from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Program (grant agreement No. 759248) and the DFG (SFB834 project number 75732319).
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Background Accumulating evidence suggests that circulating amyloidβ 1–40 (Αβ1–40), a proatherogenic aging peptide, may serve as a novel biomarker in cardiovascular disease (CVD). We aimed to explore the role of plasma Αβ1–40 and its patterns of change over time in atherosclerosis progression in postmenopausal women, a population with substantial unrecognized CVD risk beyond traditional risk factors (TRFs).

Methods In this prospective study, Αβ1–40 was measured in plasma by enzyme-linked immunosorbent assay and atherosclerosis was assessed using carotid high-resolution ultrasonography at baseline and after a median follow-up of 28.2 months in 152 postmenopausal women without history or symptoms of CVD.

Results At baseline, high Αβ1–40 was independently associated with higher carotid bulb intima-media thickness (cbIMT) and the sum of maximal wall thickness in all carotid sites (sumWT) (p < 0.05). Αβ1–40 levels increased over time and were associated with decreasing renal function (p < 0.05 for both). Women with a pattern of increasing or persistently high Αβ1–40 levels presented accelerated progression of cbIMT and maximum carotid wall thickness and sumWT (p < 0.05 for all) after adjustment for baseline Αβ1–40 levels, TRFs, and renal function.

Conclusion In postmenopausal women, a pattern of increasing or persistently high Αβ1–40 was associated with the rate of progression of subclinical atherosclerosis irrespective of its baseline levels. These findings provide novel insights into a link between Αβ1–40 and atherosclerosis progression in menopause and warrant further research to clarify the clinical value of monitoring its circulating levels as an atherosclerosis biomarker in women without clinically overt CVD.

Keywords

amyloid - atherosclerosis - menopause - aging

* The first three authors contributed equally to this work.


** Equal senior authorship.


Supplementary Material



Publikationsverlauf

Eingereicht: 17. Juni 2020

Angenommen: 10. Oktober 2020

Artikel online veröffentlicht:
17. November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Piepoli MF, Hoes AW, Agewall S. et al; ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37 (29) 2315-2381
    CrossrefPubMedGoogle Scholar
  • 2 Grundy SM, Stone NJ, Bailey AL. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139 (25) e1082-e1143
    PubMedGoogle Scholar
  • 3 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140 (11) e596-e646
    PubMedGoogle Scholar
  • 4 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2019; 41 (01) 111-188
    CrossrefPubMedGoogle Scholar
  • 5 Michos ED, Nasir K, Braunstein JB. et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006; 184 (01) 201-206
    CrossrefPubMedGoogle Scholar
  • 6 Michos ED, Vasamreddy CR, Becker DM. et al. Women with a low Framingham Risk Score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J 2005; 150 (06) 1276-1281
    CrossrefPubMedGoogle Scholar
  • 7 Hoffmann U, Massaro JM, D'Agostino Sr RB, Kathiresan S, Fox CS, O'Donnell CJ. Cardiovascular event prediction and risk reclassification by coronary, aortic, and valvular calcification in the Framingham Heart Study. J Am Heart Assoc 2016; 5 (02) e003144
    CrossrefPubMedGoogle Scholar
  • 8 Diederichsen AC, Mahabadi AA, Gerke O. et al. Increased discordance between HeartScore and coronary artery calcification score after introduction of the new ESC prevention guidelines. Atherosclerosis 2015; 239 (01) 143-149
    CrossrefPubMedGoogle Scholar
  • 9 Bertomeu-González V, Soriano Maldonado C, Bleda-Cano J. et al. Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia. Atherosclerosis 2019; 290: 80-86
    CrossrefPubMedGoogle Scholar
  • 10 Lambrinoudaki I, Armeni E, Georgiopoulos G. et al. Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. Int J Cardiol 2013; 164 (01) 70-76
    CrossrefPubMedGoogle Scholar
  • 11 Bonithon-Kopp C, Scarabin PY, Taquet A, Touboul PJ, Damé B, Guize L. Increased risk of atherosclerosis in women after the menopause. BMJ 1989; 298 (6683): 1311
    CrossrefPubMedGoogle Scholar
  • 12 Georgiopoulos GA, Lambrinoudaki I, Athanasouli F. et al. Free androgen index as a predictor of blood pressure progression and accelerated vascular aging in menopause. Atherosclerosis 2016; 247: 177-183
    CrossrefPubMedGoogle Scholar
  • 13 Ramezani Tehrani F, Behboudi-Gandevani S, Ghanbarian A, Azizi F. Effect of menopause on cardiovascular disease and its risk factors: a 9-year follow-up study. Climacteric 2014; 17 (02) 164-172
    CrossrefPubMedGoogle Scholar
  • 14 Haider A, Bengs S, Luu J. et al. Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. Eur Heart J 2020; 41 (13) 1328-1336
    CrossrefPubMedGoogle Scholar
  • 15 Kryczka KE, Kruk M, Piotrowski W. et al. Menopause improves the predictive value of common cardiovascular risk scores in women with premature coronary artery disease. Menopause 2018; 25 (04) 408-414
    CrossrefPubMedGoogle Scholar
  • 16 Desai MY, Nasir K, Braunstein JB. et al. Underlying risk factors incrementally add to the standard risk estimate in detecting subclinical atherosclerosis in low- and intermediate-risk middle-aged asymptomatic individuals. Am Heart J 2004; 148 (05) 871-877
    CrossrefPubMedGoogle Scholar
  • 17 Stamatelopoulos KS, Armeni E, Georgiopoulos G. et al. Recently postmenopausal women have the same prevalence of subclinical carotid atherosclerosis as age and traditional risk factor matched men. Atherosclerosis 2012; 221 (02) 508-513
    CrossrefPubMedGoogle Scholar
  • 18 Stakos DA, Stamatelopoulos K, Bampatsias D. et al. The Alzheimer's disease amyloid-beta hypothesis in cardiovascular aging and disease: JACC focus seminar. J Am Coll Cardiol 2020; 75 (08) 952-967
    CrossrefPubMedGoogle Scholar
  • 19 Laina A, Stellos K, Stamatelopoulos K. Vascular ageing: underlying mechanisms and clinical implications. Exp Gerontol 2018; 109: 16-30
    CrossrefPubMedGoogle Scholar
  • 20 De Meyer GR, De Cleen DM, Cooper S. et al. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res 2002; 90 (11) 1197-1204
    CrossrefPubMedGoogle Scholar
  • 21 Stamatelopoulos K, Sibbing D, Rallidis LS. et al. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol 2015; 65 (09) 904-916
    CrossrefPubMedGoogle Scholar
  • 22 Stamatelopoulos K, Pol CJ, Ayers C. et al. Amyloid-beta (1-40) peptide and subclinical cardiovascular disease. J Am Coll Cardiol 2018; 72 (09) 1060-1061
    CrossrefPubMedGoogle Scholar
  • 23 Stamatelopoulos K, Mueller-Hennessen M, Georgiopoulos G. et al. Amyloid-β (1-40) and mortality in patients with non-ST-segment elevation acute coronary syndrome: a cohort study. Ann Intern Med 2018; 168 (12) 855-865
    CrossrefPubMedGoogle Scholar
  • 24 Georgiopoulos G, Kontogiannis C, Stakos D. et al. Abdominal fat tissue echogenicity: a marker of morbid obesity. J Clin Endocrinol Metab 2019; 104 (02) 301-311
    CrossrefPubMedGoogle Scholar
  • 25 Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I. et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 2009; 54 (01) 98-105
    CrossrefPubMedGoogle Scholar
  • 26 Creatsa M, Armeni E, Stamatelopoulos K. et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism 2012; 61 (02) 193-201
    CrossrefPubMedGoogle Scholar
  • 27 Touboul PJ, Hennerici MG, Meairs S. et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 34 (04) 290-296
    CrossrefPubMedGoogle Scholar
  • 28 Wang J, Ho L, Chen L. et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117 (11) 3393-3402
    CrossrefPubMedGoogle Scholar
  • 29 Abdullah L, Paris D, Luis C. et al. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett 2007; 428 (2–3): 53-58
    CrossrefPubMedGoogle Scholar
  • 30 Okereke OI, Xia W, Selkoe DJ, Grodstein F. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 2009; 66 (10) 1247-1253
    CrossrefPubMedGoogle Scholar
  • 31 Okereke OI, Xia W, Irizarry MC. et al. Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis 2009; 16 (02) 277-285
    CrossrefPubMedGoogle Scholar
  • 32 Chiu MJ, Lue LF, Sabbagh MN, Chen TF, Chen HH, Yang SY. Long-term storage effects on stability of Αβ1-40, Αβ1-42, and total tau proteins in human plasma samples measured with immunomagnetic reduction assays. Dement Geriatr Cogn Disord Extra 2019; 9 (01) 77-86
    CrossrefPubMedGoogle Scholar
  • 33 Stamatelopoulos K, Georgiopoulos G, Athanasouli F. et al. Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis. Circ Res 2019; 125 (08) 744-758
    CrossrefPubMedGoogle Scholar
  • 34 Ghorbani A, Bhambhani V, Christenson RH. et al. Longitudinal change in galectin-3 and incident cardiovascular outcomes. J Am Coll Cardiol 2018; 72 (25) 3246-3254
    CrossrefPubMedGoogle Scholar
  • 35 Cauwenberghs N, Knez J, Thijs L. et al. Relation of insulin resistance to longitudinal changes in left ventricular structure and function in a general population. J Am Heart Assoc 2018; 7 (07) e008315
    CrossrefPubMedGoogle Scholar
  • 36 Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007; 297 (06) 611-619
    CrossrefPubMedGoogle Scholar
  • 37 Greenland P, Knoll MD, Stamler J. et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290 (07) 891-897
    CrossrefPubMedGoogle Scholar
  • 38 Khot UN, Khot MB, Bajzer CT. et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290 (07) 898-904
    CrossrefPubMedGoogle Scholar
  • 39 Appelman Y, van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis 2015; 241 (01) 211-218
    CrossrefPubMedGoogle Scholar
  • 40 Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. BMJ 2002; 325 (7356): 157-160
    CrossrefPubMedGoogle Scholar
  • 41 Bayes-Genis A, Barallat J, de Antonio M. et al. Bloodstream amyloid-beta (1-40) peptide, cognition, and outcomes in heart failure. Rev Esp Cardiol (Engl Ed) 2017; 70 (11) 924-932
    CrossrefPubMedGoogle Scholar
  • 42 Rembach A, Faux NG, Watt AD. et al; AIBL research group. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 2014; 10 (01) 53-61
    CrossrefPubMedGoogle Scholar
  • 43 Toledo JB, Vanderstichele H, Figurski M. et al; Alzheimer's Disease Neuroimaging Initiative. Factors affecting Αβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011; 122 (04) 401-413
    CrossrefPubMedGoogle Scholar
  • 44 Teixeira CJ, Veras K, de Oliveira Carvalho CR. Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period. J Mol Med (Berl) 2020; 98 (01) 39-57
    CrossrefPubMedGoogle Scholar
  • 45 Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs 2014; 74 (11) 1195-1207
    CrossrefPubMedGoogle Scholar
  • 46 Gronewold J, Klafki HW, Baldelli E. et al. Factors responsible for plasma β-amyloid accumulation in chronic kidney disease. Mol Neurobiol 2016; 53 (05) 3136-3145
    CrossrefPubMedGoogle Scholar
  • 47 Gronewold J, Todica O, Klafki HW. et al. Association of plasma β-amyloid with cognitive performance and decline in chronic kidney disease. Mol Neurobiol 2017; 54 (09) 7194-7203
    CrossrefPubMedGoogle Scholar
  • 48 Liu YH, Xiang Y, Wang YR. et al. Association between serum amyloid-beta and renal functions: implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol 2015; 52 (01) 115-119
    CrossrefPubMedGoogle Scholar
  • 49 Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X. Drug development for Alzheimer's disease: review. J Drug Target 2019; 27 (02) 164-173
    CrossrefPubMedGoogle Scholar
  • 50 Den Ruijter HM, Peters SA, Anderson TJ. et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012; 308 (08) 796-803
    CrossrefPubMedGoogle Scholar
  • 51 Amato M, Veglia F, de Faire U. et al; IMPROVE study group. Carotid plaque-thickness and common carotid IMT show additive value in cardiovascular risk prediction and reclassification. Atherosclerosis 2017; 263: 412-419
    CrossrefPubMedGoogle Scholar
  • 52 Nambi V, Chambless L, He M. et al. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J 2012; 33 (02) 183-190
    CrossrefPubMedGoogle Scholar
  • 53 Nambi V, Chambless L, Folsom AR. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55 (15) 1600-1607
    CrossrefPubMedGoogle Scholar
  • 54 Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging 2018; 19 (09) 1042-1050
    CrossrefPubMedGoogle Scholar
  • 55 Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino Sr RB. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011; 365 (03) 213-221
    CrossrefPubMedGoogle Scholar
  • 56 Mortensen MB, Fuster V, Muntendam P. et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol 2016; 68 (09) 881-891
    CrossrefPubMedGoogle Scholar